Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.

Mortality Compared to the control group, FCM administration showed a trend towards reduced risk of all-cause death (RR: 0.86, 95% CI: 0.74–1.00, P = .05, Figure 4A ) (absolute risk difference 16 (95% CI 29 to 0) fewer per 1000 patients; moderate certainty) and CV death (RR: 0.86, 95% CI: 0.72–1.02, P = .09, Figure 4B ) (absolute risk difference 12 (95% CI 24 fewer to 2 more) per 1000 patients; moderate certainty) at 1-year follow-up.

also in 33,226 other papers